Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s):  BIOAF

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.


TSXV:BTI.H - Post by User

Comment by Boomskidon Jan 27, 2023 12:48pm
227 Views
Post# 35250443

RE:So do we assume the JNJ option expired?

RE:So do we assume the JNJ option expired?
The J&J agreement was likely all about J&J exploring something with xB3 and about xB3. Such agreements usually prevent the licensee from doing anything beyond that. A new agreement is required to do more work and to advance anything worth advancing.
 
So how might such an agreement resolve itself?
  • Was xB3 successful in its job of transporting its J&J payload? (Almost certainly it was. After dozens of successful payload deliveries, it would be a shock if xB3 failed to do it again.)
  • If xb3 was successful with delivery, then did the payload work? 
  • Was the payload safe?
  • Did xB3 transport affect the payload?
  • Were there off-target delivery issues? (related to LRP-1 receptors)
  • Does the payload or xB3-payload need more research?
  • Was the study more of a study to inform J&J about the capabilities? Does J&J otherwise know what they might do with xB3?
  • Is Bioasis's current financial state and possible sale or collapse causing J&J to postpone decisions relating to xB3?
  • Does the xB3-Payload have potential commercial value?
  • Is J&J ready or willing to place the xB3 drug in its pipeline at this time? 
 
If J&J enters a deal with Bioasis then we have an answer.
 
If a deal does not happen and the option date is passed, it could mean anything from bad to fantastic. Whatever is going on, or not going on, it is very unlikely that it has anything to do with xB3.
 
jd
 
 
 
<< Previous
Bullboard Posts
Next >>